GSK’s asthma drug met its primary goal of reducing asthma attacks over a 52-week period in a late-stage trial, the British drugmaker said on Tuesday. The drug, called Depemokimab, has the potential to be the first approved ultra-long-acting biologic with a six-month dosing schedule for patients with severe asthma, GSK said in a statement.
Read more
